Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Cassava Sciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

AUSTIN, TEXAS, AUG. 14, 2025 (GLOBE NEWSWIRE) -- CASSAVA SCIENCES, INC. (NASDAQ: SAVA, CASSAVA, THE COMPANY), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NOVEL, INVESTIGATIONAL TREATMENTS FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS SUCH AS TUBEROUS SCLEROSIS COMPLEX (TSC)-RELATED EPILEPSY, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 AND PROVIDED A BUSINESS UPDATE.

CASSAVA REPORTS Q2 2025 FINANCIALS RESULTS AND PROVIDES BUSINESS UPDATE

AUSTIN, TEXAS, AUG. 07, 2025 (GLOBE NEWSWIRE) -- CASSAVA SCIENCES, INC. (NASDAQ: SAVA, CASSAVA, THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NOVEL, INVESTIGATIONAL TREATMENTS FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY ANNOUNCED THE APPOINTMENT OF DR. JOSEPH HULIHAN AS CHIEF MEDICAL OFFICER (CMO). DR. HULIHAN WILL DEVOTE APPROXIMATELY HALF OF HIS PROFESSIONAL TIME TO CASSAVA, ADVISING ON THE CLINICAL DEVELOPMENT OF SIMUFILAM, CASSAVA'S INVESTIGATIONAL CANDIDATE FOR THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX (TSC)-RELATED EPILEPSY.

CASSAVA SCIENCES APPOINTS DR. JOSEPH HULIHAN AS CHIEF MEDICAL OFFICER

AUSTIN, TEXAS, AUG. 04, 2025 (GLOBE NEWSWIRE) -- CASSAVA SCIENCES, INC. (NASDAQ: SAVA, CASSAVA, THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NOVEL TREATMENTS FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY REPORTED POSITIVE PRECLINICAL RESULTS OF A STUDY EVALUATING SIMUFILAM IN A WELL-ACCEPTED MOUSE MODEL OF TUBEROUS SCLEROSIS COMPLEX (TSC)-RELATED EPILEPSY.

CASSAVA SCIENCES REPORTS POSITIVE PRECLINICAL STUDY EVALUATING SIMUFILAM FOR TSC-RELATED EPILEPSY

DATA SHOW THAT SIMUFILAM REDUCED SEIZURE ACTIVITY IN A PRECLINICAL MOUSE MODEL PRESENTATION ALSO HIGHLIGHTS FAVORABLE HUMAN SAFETY DATA FROM 1,929 PATIENT PHASE 3 PROGRAM AUSTIN, TEXAS, JUNE 30, 2025 (GLOBE NEWSWIRE) -- CASSAVA SCIENCES, INC. (NASDAQ: SAVA, CASSAVA, THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NOVEL, INVESTIGATIONAL TREATMENTS FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY ANNOUNCED THAT THE COMPANY PRESENTED A POSTER AT THE TSC INTERNATIONAL RESEARCH CONFERENCE (TSC 2025) HELD JUNE 26-28, 2025 IN BETHESDA, MD. THE POSTER, AVAILABLE ON THE COMPANY WEBSITE VIA THIS LINK, DETAILED TWO IMPORTANT OBSERVATIONS THAT SUPPORT CASSAVA'S PLAN TO INITIATE HUMAN CLINICAL STUDIES IN H1 2026 TO EVALUATE SIMUFILAM AS A TREATMENT FOR TUBEROUS SCLEROSIS COMPLEX (TSC)-RELATED EPILEPSY: PRECLINICAL PROOF-OF-CONCEPT: TREATMENT WITH SIMUFILAM ALLEVIATED NEURONAL ABNORMALITIES AND REDUCED SEIZURE FREQUENCY BY 60% COMPARED TO VEHICLE IN A MOUSE MODEL OF FOCAL ONSET SEIZURES.

CASSAVA PRESENTS PROMISING PRECLINICAL SIMUFILAM DATA AT TSC ALLIANCE MEETING

AS SVP, NEUROSCIENCE, DR. BORDEY WILL LEAD CASSAVA'S ONGOING RESEARCH AND DEVELOPMENT EFFORTS DR. BORDEY TO DIRECT THE SCIENTIFIC EVALUATION OF SIMUFILAM IN TSC-RELATED EPILEPSY, AND POTENTIALLY ADDITIONAL PIPELINE INDICATIONS AUSTIN, TEXAS, MAY 01, 2025 (GLOBE NEWSWIRE) -- CASSAVA SCIENCES, INC. (NASDAQ: SAVA, CASSAVA, THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NOVEL, INVESTIGATIONAL TREATMENTS FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY ANNOUNCED THAT ANGLIQUE BORDEY, PHD, HAS JOINED THE COMPANY AS SENIOR VICE PRESIDENT (SVP), NEUROSCIENCE, WHILE CONTINUING HER TENURED ACADEMIC POSITION AT YALE SCHOOL OF MEDICINE ON A PART TIME BASIS. DR. BORDEY WILL BE PRIMARILY RESPONSIBLE FOR LEADING CASSAVA'S RESEARCH AND DEVELOPMENT EFFORTS.

CASSAVA APPOINTS ANGLIQUE BORDEY, PHD, TO ENHANCE PRECLINICAL PROGRAM IN TSC

AUSTIN, TEXAS, APRIL 21, 2025 (GLOBE NEWSWIRE) -- CASSAVA SCIENCES, INC. (NASDAQ: SAVA, CASSAVA, THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NOVEL, INVESTIGATIONAL TREATMENTS, INCLUDING SIMUFILAM, FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS SUCH AS TUBEROUS SCLEROSIS COMPLEX (TSC)-RELATED EPILEPSY, TODAY ANNOUNCED THE RETIREMENT OF JAMES W. KUPIEC, MD, CHIEF MEDICAL OFFICER, EFFECTIVE MAY 9, 2025. THE COMPANY ALSO APPOINTED JACK MOORE, PHD, AS SENIOR VICE PRESIDENT, CLINICAL DEVELOPMENT, REPORTING TO RICK BARRY, CHIEF EXECUTIVE OFFICER.

CASSAVA ANNOUNCES RETIREMENT OF CHIEF MEDICAL OFFICER, DR. JIM KUPIEC, AND APPOINTMENT OF DR. JACK MOORE AS SENIOR VICE PRESIDENT, CLINICAL DEVELOPMENT

AUSTIN, TEXAS, MARCH 25, 2025 (GLOBE NEWSWIRE) -- CASSAVA SCIENCES, INC. (NASDAQ: SAVA, CASSAVA, THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING A NOVEL, INVESTIGATIONAL TREATMENT FOR CENTRAL NERVOUS SYSTEM DISORDERS, INCLUDING ALZHEIMER'S DISEASE (AD) DEMENTIA AND TUBEROUS SCLEROSIS COMPLEX (TSC)-RELATED EPILEPSY, TODAY SHARED TOPLINE RESULTS FROM THE PHASE 3 REFOCUS-ALZ STUDY OF SIMUFILAM IN MILD-TO-MODERATE AD.

CASSAVA SCIENCES REPORTS TOPLINE PHASE 3 REFOCUS-ALZ DATA

AUSTIN, TEXAS, MARCH 03, 2025 (GLOBE NEWSWIRE) -- CASSAVA SCIENCES, INC. (NASDAQ: SAVA, CASSAVA, THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NOVEL, INVESTIGATIONAL TREATMENTS FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, INCLUDING ALZHEIMER'S DISEASE AND TUBEROUS SCLEROSIS COMPLEX (TSC)-RELATED SEIZURES, TODAY REPORTED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 AND PROVIDED A BUSINESS UPDATE.

CASSAVA SCIENCES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

NEW YORK, NY / ACCESS NEWSWIRE / FEBRUARY 10, 2025 / IF YOU SUFFERED A LOSS ON YOUR CASSAVA SCIENCES, INC. (NASDAQ:SAVA) INVESTMENT AND WANT TO LEARN ABOUT A POTENTIAL RECOVERY UNDER THE FEDERAL SECURITIES LAWS, FOLLOW THE LINK BELOW FOR MORE INFORMATION: HTTPS://ZLK.COM/PSLRA-1/CASSAVA-SCIENCES-INC-LAWSUIT-SUBMISSION-FORM?PRID=128534&WIRE=1 OR CONTACT JOSEPH E. LEVI, ESQ.

CASSAVA SCIENCES, INC. SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT LEVI & KORSINSKY BEFORE FEBRUARY 10, 2025 TO DISCUSS YOUR RIGHTS  SAVA

NEW YORK, FEB. 10, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN CASSAVA SCIENCES, INC. ("CASSAVA SCIENCES, INC." OR THE "COMPANY") (NASDAQ: SAVA) OF A CLASS ACTION SECURITIES LAWSUIT.

Cassava Sciences, Inc.

SAVA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Cassava Sciences, Inc.

SAVA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SAVA